Arsenal Medical Announces Complete Enrollment of the Initial Cohort in the EMBO-02 Study Assessing NeoCast™ for the Treatment of Chronic Subdural Hematoma
WALTHAM, Mass. — Arsenal Medical, a clinical-stage company developing medical devices from innovative biomaterials, today announced the complete enrollment of an initial cohort of 10 patients in the EMBO-02 clinical study of NeoCast™ to treat chronic subdural hematomas (cSDH) across three sites in Australia. NeoCast is a next-generation, non-adhesive, solvent-free, liquid embolic material designed for deep distal penetration. EMBO-02 is an open-label, multi-center, prospective clinical trial to evaluate the early safety and feasibility of NeoCast to embolize target vessels of the subject’s middle meningeal artery (MMA) to treat cSDH.
